Eisai has made three key appointments for its oncology and neurology business groups. Avinash Desai, M.D., has been made VP, Americas Oncology Medical Affairs for the Oncology Business Group (OBG) at Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd. Beyhan Zaim was appointed VP Commercial Development & Alzheimer’s Disease Global Lead, Neurology Business Group. Paul Hawthorne is now senior VP, U.S. Commercial, Neurology Business Group.
Fredrik Wiklund has been made chief operating officer of Bioniz Therapeutics Inc.
More than two thirds of adults with uncontrolled asthma in the United States mistakenly believe that their condition is under control, according to the results of a survey released in May by GlaxoSmithKline. The survey results, researchers say, may suggest uncontrolled patients feel a false sense of confidence in managing their condition that may be driving recurring symptoms, and doctor, emergency room and urgent care visits.
The point of care health information services company ContextMedia:Health has announced the launch of its New Patient Start (NPS) Program, a new model that aims to change the way point-of-care programs are purchased and evaluated by pharmaceutical companies. ContextMedia:Health’s New Patient Start Program, company executives say, offers the ability for its brand partners to purchase marketing outcomes at no risk, and at a favorable ROI.
It’s a challenge to find and select the right consultants for a clinical study or drug trial.
Company continues to expand and disrupt the industry as Agency of the Future TORONTO, ON – June 1, 2016 – Start spreading the news – Klick Health today announced […]
Omnicom Health Group announced the leadership team for TBWA\WorldHealth, the new agency created by the combination of two healthcare specialist agencies, Corbett and LLNS.
Theratechnologies Inc. announces that it has been notified by its partner, TaiMed Biologics Inc., of the preliminary results for the primary end point of the phase III trial with ibalizumab in patients with multi-drug resistant HIV-1 (TMB-301).
Join the GTO Group for a free webinar exploring how marketing, media, design, and technology are converging in order to effectively reach and empower patients, caregivers, and HCPs.
A white paper from Aesica, a leading pharmaceutical contract development and manufacturing organization (CDMO) for both APIs and finished dosage forms. Serialization has emerged as a complex challenge for […]
